Conference Proceedings
Ibrutinib/rituximab versus placebo/rituximab in Waldenstrom's Macroglobulinemia (WM): results of a randomized phase 3 trial
C Buske, A Tedeschi, J Trotman, R Garcia-Sanz, D MacDonald, V Leblond, B Mahe, C Herbaux, CS Tam, ML Palomba, J Matous, C Shustik, E Kastritis, SP Treon, J Li, Z Salman, T Graef, MA Dimopoulos
ONCOLOGY RESEARCH AND TREATMENT | KARGER | Published : 2018
Grants
Funding Acknowledgements
Christian Buske: Advisory Role: Roche, Janssen, Pfizer, Gilead; Expert Testimony: Roche, Janssen; Other Financial Relationships: Speakers Bureau: Roche, Janssen, Pfizer, GileadMeletios A. Dimopoulos: Advisory Role: Janssen, Celgene, Takeda, Amgen, Novartis; Financing of Scientific Research: Janssen, Celgene, Takeda, Amgen, Novartis; Expert Testimony: Genesis Pharma